David Einstein
@davidjeinstein
Disease Group Leader, GU Medical Oncology @BIDMChealth @df_hcc, Asst Prof @harvardmed, dad, cyclist, Far Side superfan
You might like
Out now in @JCO_ASCO , @Merregan @Dr_RaviMadan Julia Stevens, @Uromigos David McDermott, and I ask how to approach tx goals & endpoints in biochemically recurrent prostate cancer in the EMBARK era: · Is metastasis-free survival (MFS) meaningful? · Is extending MFS “worth it”?
Tonight @ Boston Prostate Cancer Support Group: Dr. Ali Baghian @BIDMC_CancerCtr tells about how to interpret your pathology results! 6 pm subgroups, 7 pm main speaker Bostonprostatecancer.org
It’s hard to believe Americas 🇺🇸 🇨🇦 3-0 down in the Uromigos Cup 🏆 . Weekly photos from each team from around the world wins points . ❤️ =points. Can the Americas 🇺🇸🇨🇦 catch up ? Here is @walterstadler5 in Chicago. @OncoAlert @montypal @crisuarez08 @DrChoueiri
Stay Tune for Coverage of @Uromigos Live 2025 Direct from Nashville, TN🇺🇸 #UromigosLIVE25 An honor for OncoAlert 🚨to attend and our gratitude to OUR friends the UROMIGOS for the invitation!! See you in Nashville!! @tompowles1 @brian_rini @uromigosjapan @TresUramigas
Endpoints matter especially in recurrent PC… pubmed.ncbi.nlm.nih.gov/38754067/ Treatment-Free Survival in trials of MDT +/- systemic therapy commentary under review…
The great @angela_jia_ reminding us of the importance of endpoint selection. Pros and cons of surrogates. Critical to keep patient QOL at the forefront BCR not a surrogate for OS in #ProstateCancer #ASTRO25 @ASTRO_org
Prelude to PSMA-DC
🚨 Phase II LUNAR RCT: 177Lu-PSMA Neoadj to Ablative SBRT for Oligorecur PCa @urotoday #ASTRO25 @AmarUKishan 2 cycles of neoadjuvant 177Lu-PSMA PNT2002 + SBRT to all mets vs SBRT to all mets ⚡️PFS: HR 0.37, 95% CI 0.22-61 ⚡️Hormone-Rx FS: HR 0.40, 95% CI 0.22-0.71 ⚡️Gr 3…
Excellent! Long-term systemic therapy will inevitably improve MFS, but how can we maximize time off treatment? Time for novel endpoints to capture this!
✨ 🔥🔥New Editorial in @EUplatinum EMBARK puts ARPIs in the spotlight, but where does RT stand in high-risk BCR? 💡 Perspectives, open questions, insights on imaging, MDT & integration 🚀 #radoncGUcommunity #PCa sciencedirect.com/science/articl…
Love to see trials framed around Treatment-Free Survival!
Excited to share our recent @LancetOncology publication on sequential SBRT for oligometastatic clear cell RCC. Our outcomes show excellent outcomes in 121 patients with 1-5 metastases. @MDAndersonNews @myriadgenetics authors.elsevier.com/a/1ljMf5EIIgTS…
“The question is not should we or should we not stage using #PSMA-PET, but how to treat patients most properly using the information from a PSMA-PET,” said Thomas Hope, MD” @medscape #ProstateCancer medscape.com/viewarticle/ps…
⭐️ Giuseppe Carnevali Endowed Lecture ⭐️ “Unravelling the Mysteries of Kidney Cancer – A Journey from Genetics to Immunology” Dr. Samra Turajlic, MD @TheCrick A masterclass in Kidney Cancer from genetics 🧬 to immunogenicity 🦠to pearls that impact clinical care 🩺 !
Patients with prostate cancer and their caretakers--join the Boston Prostate Cancer Support Group tonight, 6-8 pm EDT. bostonprostatecancer.org 6-7: Patient-led subgroups 7-8: @AtishChoudhury from @DanaFarber_GU speaks on emerging therapeutics!
Does the addition of MDT to standard of care continuous ADT improve outcomes for oligomet prostate ca? Happy to share the results of EXTEND evaluating this question alongside PI @ChadTangMD & many others
Brief 🧵 1/ How common is *failure* of modern active surveillance (AS) for #ProstateCancer (PCa)? Which patients are at higher risk? Spoiler 🚨: it’s pretty simple @EurUrolOncol @UroToday @OncoAlert @PCF_Science @gu_onc @AmerUrological @Uroweb
👥 Connect, learn, & collaborate with your peers! Join Dr. Smith, Dr. Gao, @CaPsurvivorship, @davidjeinstein, @RickLee6 & @VincentWenxinXu at the Genitourinary Cancers State of the Science Summit on July 22! Register today: hubs.li/Q03wwJx20 @MGHCancerCenter #SOSSconnects
Do #PSMA+ findings in #BCR #ProstateCancer require immediate treatment? NO based on emerging data @theNCI Appreciate @TiansterZhang @urotoday for the opportunity to discuss Ongoing trial of PSMA scans in BCR is still enrolling: shorturl.at/36nGQ shorturl.at/FDFKl
Looking forward to this!
The 4th live Uromigos meeting is happening on 7th & 8th Nov ‘25 in Nashville. It’s going to have an international flavour with America’s 🇺🇸 🇨🇦 vs Eurasia 🇯🇵 🇨🇳 🇮🇳 🇦🇺 🇪🇺 Uromigos Cup competition (details to follow). Sessions ranging from ADCs in MIBC to the changing shape of…
How should patients think about tough treatment decisions for biochemically recurrent prostate cancer? @BIDMC_HOFellows Lauren O'Loughlin shows how we talk about BCR in our clinic for @urotoday. urotoday.com/recent-abstrac…
Very important risk-adapted study!
What should we do for #ProstateCancer patients with #PSMA+ #BCR? While we can use any treatment do we NEED to? Stop by tomorrow abstract BD# 297. Monday 9am-noon The answer is pretty clear… #ASCO25 @ASCO @theNCI
Updated data from #PSMA monitoring study in #BCR #ProstateCancer @ASCO #ASCO25 Stop by & see our poster on Monday morning You can see what happens to this pt at 6 months 10+ LNs How would you have managed this case? Trial continues to accrue @theNCI clinicaltrials.gov/study/NCT05588…
Massachusetts Prostate Cancer Coalition annual virtual symposium starting in 1 hour! masspcc.org/events/
United States Trends
- 1. Good Sunday 52K posts
- 2. Discussing Web3 N/A
- 3. #HealingFromMozambique 18.7K posts
- 4. #sundayvibes 4,579 posts
- 5. Wordle 1,576 X N/A
- 6. Blessed Sunday 17K posts
- 7. Trump's FBI 11.2K posts
- 8. Biden FBI 17.6K posts
- 9. Gilligan's Island 5,541 posts
- 10. Coco Gauff N/A
- 11. Macrohard 9,434 posts
- 12. The CDC 32.2K posts
- 13. Dissidia 7,609 posts
- 14. Go Broncos 1,275 posts
- 15. Pegula 5,608 posts
- 16. Nor'easter 1,693 posts
- 17. FDV 5min 2,184 posts
- 18. Utah 25.3K posts
- 19. Market Cap Surges N/A
- 20. QUICK TRADE 2,182 posts
You might like
-
Dan George
@Daniel_J_George -
Guru P. Sonpavde, MD
@sonpavde -
Scott Tagawa
@DrScottTagawa -
Dana-Farber Lank Center for Genitourinary Oncology
@DanaFarber_GU -
Atish Choudhury, MD PhD
@AtishChoudhury -
joaquim bellmunt
@OncoBellmunt -
Misha Beltran
@mishabeltran -
Andrea Apolo, M.D.
@apolo_andrea -
Tanya Dorff
@TDorffOnc -
Hans Hammers
@HHammersMD -
Andrew Armstrong
@AarmstrongDuke -
Benjamin L Maughan
@maughanonc -
Howard Soule
@soulehoward1 -
Charlene Mantia
@CharleneMantia -
Josh Lang
@JoshLangMD
Something went wrong.
Something went wrong.